<DOC>
	<DOCNO>NCT00756106</DOCNO>
	<brief_summary>RATIONALE : Diagnostic procedure , MRI , may help learn well radiation therapy chemotherapy work kill tumor cell allow doctor plan good treatment . PURPOSE : This clinical trial study MRI scan see well evaluate effect radiation therapy chemotherapy patient newly diagnose glioblastoma multiforme anaplastic glioma .</brief_summary>
	<brief_title>MRI Scans Evaluating Effects Radiation Therapy Chemotherapy Patients With Newly Diagnosed Glioblastoma Multiforme Anaplastic Glioma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To quantitatively compare relative cerebral blood volume/flow , mean transit time , mean vessel diameter measure perfusion-weighted MRI , , chemoradiotherapy patient newly diagnose glioblastoma multiforme . - To measure permeability-surface area product voxel-by-voxel basis , , chemoradiotherapy patient . - To measure full water self-diffusion tensor voxel-by-voxel basis , , chemoradiotherapy patient . - To compare tensor fractional anisotropy , , chemoradiotherapy patient . - To compare relative regional concentration choline , N-acetyl-asparate , myoinositol measure magnetic resonance spectroscopy , , chemoradiotherapy interrogate cell membrane turnover , neuronal integrity , glial reaction . - To test affect short period 100 % oxygen inhalation image tumor surround tissue region interest , specifically cerebral blood volume change area compare room air . Secondary - To collect blood urine sample correlation analysis imaging change , molecular marker ( include genetic marker ) , clinical outcome glioblastoma multiforme ( phenotypic information ) . - To correlate blood urine biomarkers blood genetic marker tumor expression marker . OUTLINE : Patients undergo radiotherapy daily 5 day week 6 week . Patients also receive oral temozolomide daily 7 day week radiotherapy . After completion chemoradiotherapy , patient receive oral temozolomide daily 5 day . Treatment temozolomide repeat every 28 day absence disease progression unacceptable toxicity . Patients undergo MRI , include perfusion- diffusion-weighted MRI , diffusion tensor imaging , magnetic resonance spectroscopy prior initiation chemoradiotherapy , weekly chemoradiotherapy , monthly tumor progression completion 6 course post chemoradiotherapy . After completion study treatment , patient follow annually .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose anaplastic glioma ( WHO grade III ) glioblastoma multiforme ( WHO grade IV ) Measurable disease Residual tumor size surgery ≥ 1 cm one dimension Planning undergo standard chemoradiotherapy temozolomide PATIENT CHARACTERISTICS : Glomerular filtration rate ≥ 60 mL/min Mini Mental Status Exam score &gt; 15 Sufficiently competent give inform consent Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception 2 month completion study treatment No contraindication MRI use contrast agent gadolinium , include follow : Claustrophobia Metallic object implant medical device ( e.g. , cardiac pacemaker , aneurysm clip , surgical clip , prosthesis , artificial heart , valve steel part , metal fragment , shrapnel , tattoo near eye , steel implant ) Sickle cell disease Renal failure High risk kidney disease ( e.g. , age &gt; 60 year , diabetes , history systemic lupus erythematosus multiple myeloma ) No known history chronic obstructive pulmonary disease emphysema No coexist condition , judgement investigator , may increase risk patient PRIOR CONCURRENT THERAPY : See Disease Characteristics NonVEGF investigational agent allow No concurrent chemotherapy ( temozolomide ) No concurrent electron , proton , particle , implant radiotherapy No concurrent stereotactic radiosurgery No concurrent antiVEGF antitumor agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic ependymoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult mixed glioma</keyword>
</DOC>